These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27275478)

  • 61. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review.
    Perazzoli G; García-Valdeavero OM; Peña M; Prados J; Melguizo C; Jiménez-Luna C
    Metabolites; 2023 Jul; 13(7):. PubMed ID: 37512579
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular biology of pancreatic cancer: potential clinical implications.
    Sakorafas GH; Tsiotos GG
    BioDrugs; 2001; 15(7):439-52. PubMed ID: 11520255
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Whole-Genome Analysis of De Novo Somatic Point Mutations Reveals Novel Mutational Biomarkers in Pancreatic Cancer.
    Ghareyazi A; Mohseni A; Dashti H; Beheshti A; Dehzangi A; Rabiee HR; Alinejad-Rokny H
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503185
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pancreatic Cancer from Molecular Pathways to Treatment Opinion.
    Karanikas M; Esempidis A; Chasan ZT; Deftereou T; Antonopoulou M; Bozali F; Amarantidis K; Man YG
    J Cancer; 2016; 7(10):1328-39. PubMed ID: 27390608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapeutic Advances for Pancreatic Cancer: a Slow and Challenging Feat that Continues to Evolve.
    Blanquicett CJ; Aguirre LE
    Acta Sci Gastron Disord; 2021 Jul; 4(7):50-52. PubMed ID: 34414366
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
    Vera R; Dotor E; Feliu J; González E; Laquente B; Macarulla T; Martínez E; Maurel J; Salgado M; Manzano JL
    Clin Transl Oncol; 2016 Dec; 18(12):1172-1178. PubMed ID: 27896637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular biology of pancreatic cancer: how useful is it in clinical practice?
    Sakorafas GH; Smyrniotis V
    JOP; 2012 Jul; 13(4):332-7. PubMed ID: 22797383
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody drug conjugates: hitting the mark in pancreatic cancer?
    Wittwer NL; Brown MP; Liapis V; Staudacher AH
    J Exp Clin Cancer Res; 2023 Oct; 42(1):280. PubMed ID: 37880707
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The molecular targets for the diagnosis and treatment of pancreatic cancer.
    Strimpakos AS; Syrigos KN; Saif MW
    Gut Liver; 2010 Dec; 4(4):433-49. PubMed ID: 21253292
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer.
    Haycox A; Lombard M; Neoptolemos J; Walley T
    Aliment Pharmacol Ther; 1998 Oct; 12(10):937-48. PubMed ID: 9798798
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Systemic treatment for advanced pancreatic cancer.
    Leowattana W; Leowattana P; Leowattana T
    World J Gastrointest Oncol; 2023 Oct; 15(10):1691-1705. PubMed ID: 37969416
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers.
    Kim EJ; Semrad TJ; Bold RJ
    Expert Opin Investig Drugs; 2015 Jun; 24(6):781-94. PubMed ID: 25809274
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pancreatic cancer, treatment options, and GI-4000.
    Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
    Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches.
    Gu M; Liu Y; Xin P; Guo W; Zhao Z; Yang X; Ma R; Jiao T; Zheng W
    Cancer Lett; 2024 Apr; 588():216738. PubMed ID: 38401887
    [TBL] [Abstract][Full Text] [Related]  

  • 75. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.
    Kunk PR; Bauer TW; Slingluff CL; Rahma OE
    J Immunother Cancer; 2016; 4():14. PubMed ID: 26981244
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives.
    Cassese G; Han HS; Yoon YS; Lee JS; Lee B; Cubisino A; Panaro F; Troisi RI
    World J Gastrointest Oncol; 2023 Jun; 15(6):911-924. PubMed ID: 37389109
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New insights into pancreatic cancer stem cells.
    Rao CV; Mohammed A
    World J Stem Cells; 2015 Apr; 7(3):547-55. PubMed ID: 25914762
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
    Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
    J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
    Winer E; Gralow J; Diller L; Karlan B; Loehrer P; Pierce L; Demetri G; Ganz P; Kramer B; Kris M; Markman M; Mayer R; Pfister D; Raghavan D; Ramsey S; Reaman G; Sandler H; Sawaya R; Schuchter L; Sweetenham J; Vahdat L; Schilsky RL;
    J Clin Oncol; 2009 Feb; 27(5):812-26. PubMed ID: 19103723
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evolution of novel therapeutic options for pancreatic cancer.
    Saluja AK; Dudeja V; Banerjee S
    Curr Opin Gastroenterol; 2016 Sep; 32(5):401-407. PubMed ID: 27454027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.